PIK3CA and gastric carcinoma: PIK3CA amplification was found in 15.7%(8 of 51) and 71.8%(89 of 124) cases in subtype2 and subtype3, respectively, which has been reported to be associated with sensitivity to several drugs in epithelial ovarian cancer, stomach carcinoma and head and neck squamous cell carcinoma26–28.